Bromodomain Containing Protein 4 - Pipeline Review, H2 2020
![](/report_cover/2671/bromodomain-containing-protein-4-pipeline-review-h1-2020_en.gif)
Bromodomain Containing Protein 4 - Pipeline Review, H2 2020
Summary
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Bromodomain-containing protein 4 is a protein encoded by the BRD4 gene. It plays a key role in transmission of epigenetic memory across cell divisions and transcription regulation. It promotes phosphorylation of Ser-2 of the C-terminal domain (CTD) of RNA polymerase II. It acts as a regulator of p53/TP53-mediated transcription.
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) pipeline Target constitutes close to 41 molecules. Out of which approximately 31 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 8, 16 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 6 and 4 molecules, respectively.
Report covers products from therapy areas Oncology, Dermatology, Infectious Disease, Immunology, Musculoskeletal Disorders, Cardiovascular, Central Nervous System, Genetic Disorders, Genito Urinary System And Sex Hormones and Respiratory which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Solid Tumor, Multiple Myeloma (Kahler Disease), Diffuse Large B-Cell Lymphoma, Ovarian Cancer, Triple-Negative Breast Cancer (TNBC), Colorectal Cancer, Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Atopic Dermatitis (Atopic Eczema), Human Immunodeficiency Virus (HIV) Infections (AIDS), Leukemia, Lung Cancer, Melanoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Pancreatic Cancer, Small-Cell Lung Cancer, Breast Cancer, Colon Cancer, Fallopian Tube Cancer, Follicular Lymphoma, Hematological Tumor, Lymphoma, Myelofibrosis, Myeloproliferative Disorders, Neuroblastoma, Non-Hodgkin Lymphoma, Peritoneal Cancer, Psoriasis, Rheumatoid Arthritis, Systemic Sclerosis (Scleroderma), Advanced Malignancy, B-Cell Non-Hodgkin Lymphoma, Basal Cell Carcinoma (Basal Cell Epithelioma), Cervical Cancer, Chronic Kidney Disease (Chronic Renal Failure), Chronic Lymphocytic Leukemia (CLL), Cognitive Disorders, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Coronavirus Disease 2019 (COVID-19), Epithelial Ovarian Cancer, Fabry Disease, Facioscapulohumeral Muscular Dystrophy (FSHD), Fibrosis, Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Idiopathic Pulmonary Fibrosis, Inflammation, Malignant Mesothelioma, Mantle Cell Lymphoma, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Liver Cancer, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Pancreatic Ductal Adenocarcinoma, Peripheral Arterial Disease (PAD)/Peripheral Vascular Disease (PVD), Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Primary Myelofibrosis, Prostate Cancer, Pulmonary Arterial Hypertension, Renal Cell Carcinoma, Systemic Lupus Erythematosus, Uterine Cancer, Uveal Melanoma, Vaginal Cancer, Vascular Dementias and Vulvar Cancer.
The latest report Bromodomain Containing Protein 4 - Pipeline Review, H2 2020, outlays comprehensive information on the Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Bromodomain-containing protein 4 is a protein encoded by the BRD4 gene. It plays a key role in transmission of epigenetic memory across cell divisions and transcription regulation. It promotes phosphorylation of Ser-2 of the C-terminal domain (CTD) of RNA polymerase II. It acts as a regulator of p53/TP53-mediated transcription.
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) pipeline Target constitutes close to 41 molecules. Out of which approximately 31 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 8, 16 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 6 and 4 molecules, respectively.
Report covers products from therapy areas Oncology, Dermatology, Infectious Disease, Immunology, Musculoskeletal Disorders, Cardiovascular, Central Nervous System, Genetic Disorders, Genito Urinary System And Sex Hormones and Respiratory which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Solid Tumor, Multiple Myeloma (Kahler Disease), Diffuse Large B-Cell Lymphoma, Ovarian Cancer, Triple-Negative Breast Cancer (TNBC), Colorectal Cancer, Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Atopic Dermatitis (Atopic Eczema), Human Immunodeficiency Virus (HIV) Infections (AIDS), Leukemia, Lung Cancer, Melanoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Pancreatic Cancer, Small-Cell Lung Cancer, Breast Cancer, Colon Cancer, Fallopian Tube Cancer, Follicular Lymphoma, Hematological Tumor, Lymphoma, Myelofibrosis, Myeloproliferative Disorders, Neuroblastoma, Non-Hodgkin Lymphoma, Peritoneal Cancer, Psoriasis, Rheumatoid Arthritis, Systemic Sclerosis (Scleroderma), Advanced Malignancy, B-Cell Non-Hodgkin Lymphoma, Basal Cell Carcinoma (Basal Cell Epithelioma), Cervical Cancer, Chronic Kidney Disease (Chronic Renal Failure), Chronic Lymphocytic Leukemia (CLL), Cognitive Disorders, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Coronavirus Disease 2019 (COVID-19), Epithelial Ovarian Cancer, Fabry Disease, Facioscapulohumeral Muscular Dystrophy (FSHD), Fibrosis, Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Idiopathic Pulmonary Fibrosis, Inflammation, Malignant Mesothelioma, Mantle Cell Lymphoma, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Liver Cancer, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Pancreatic Ductal Adenocarcinoma, Peripheral Arterial Disease (PAD)/Peripheral Vascular Disease (PVD), Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Primary Myelofibrosis, Prostate Cancer, Pulmonary Arterial Hypertension, Renal Cell Carcinoma, Systemic Lupus Erythematosus, Uterine Cancer, Uveal Melanoma, Vaginal Cancer, Vascular Dementias and Vulvar Cancer.
The latest report Bromodomain Containing Protein 4 - Pipeline Review, H2 2020, outlays comprehensive information on the Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4)
- The report reviews Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics and enlists all their major and minor projects
- The report assesses Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Overview
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Companies Involved in Therapeutics Development
AbbVie Inc
AstraZeneca Plc
Avalyn Pharma Inc
Boehringer Ingelheim International GmbH
Fratagene Therapeutics Srl
Lead Discovery Center GmbH
Prous Institute for Biomedical Research SA
TopiVert Ltd
Turning Point Therapeutics Inc
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Drug Profiles
bosutinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Inhibit SRC for Friedreich Ataxia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ilorasertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JRP-890 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Dormant Products
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Discontinued Products
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Overview
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Companies Involved in Therapeutics Development
AbbVie Inc
AstraZeneca Plc
Avalyn Pharma Inc
Boehringer Ingelheim International GmbH
Fratagene Therapeutics Srl
Lead Discovery Center GmbH
Prous Institute for Biomedical Research SA
TopiVert Ltd
Turning Point Therapeutics Inc
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Drug Profiles
bosutinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Inhibit SRC for Friedreich Ataxia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ilorasertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JRP-890 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Dormant Products
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Discontinued Products
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indications, H2 2020
Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020
Number of Products under Development by Indications, H2 2020 (Contd..2), H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products under Investigation by Universities/Institutes, H2 2020
Products under Investigation by Universities/Institutes, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by AbbVie Inc, H2 2020
Pipeline by AstraZeneca Plc, H2 2020
Pipeline by Avalyn Pharma Inc, H2 2020
Pipeline by Boehringer Ingelheim International GmbH, H2 2020
Pipeline by Fratagene Therapeutics Srl, H2 2020
Pipeline by Lead Discovery Center GmbH, H2 2020
Pipeline by Prous Institute for Biomedical Research SA, H2 2020
Pipeline by TopiVert Ltd, H2 2020
Pipeline by Turning Point Therapeutics Inc, H2 2020
Dormant Products, H2 2020
Dormant Products, H2 2020 (Contd..1), H2 2020
Dormant Products, H2 2020 (Contd..2), H2 2020
Discontinued Products, H2 2020
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indications, H2 2020
Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020
Number of Products under Development by Indications, H2 2020 (Contd..2), H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products under Investigation by Universities/Institutes, H2 2020
Products under Investigation by Universities/Institutes, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by AbbVie Inc, H2 2020
Pipeline by AstraZeneca Plc, H2 2020
Pipeline by Avalyn Pharma Inc, H2 2020
Pipeline by Boehringer Ingelheim International GmbH, H2 2020
Pipeline by Fratagene Therapeutics Srl, H2 2020
Pipeline by Lead Discovery Center GmbH, H2 2020
Pipeline by Prous Institute for Biomedical Research SA, H2 2020
Pipeline by TopiVert Ltd, H2 2020
Pipeline by Turning Point Therapeutics Inc, H2 2020
Dormant Products, H2 2020
Dormant Products, H2 2020 (Contd..1), H2 2020
Dormant Products, H2 2020 (Contd..2), H2 2020
Discontinued Products, H2 2020
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
COMPANIES MENTIONED
AbbVie Inc
Amgen Inc
Arvinas Inc
AstraZeneca Plc
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Bromodomain Pharmaceuticals Inc
C4 Therapeutics Inc
Checkpoint Therapeutics Inc
Constellation Pharmaceuticals Inc
CSPC Pharmaceutical Group Ltd
Epigene Therapeutics Inc
Kainos Medicine Inc
Ningbo Wenda Pharma
OHM Oncology
Oncopia Therapeutics LLC
Phio Pharmaceuticals Corp
Plexxikon Inc
Red Glead Discovery AB
Resverlogix Corp
SignalRx Pharmaceuticals Inc
Zenith Epigenetics Ltd
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
COMPANIES MENTIONED
AbbVie Inc
Amgen Inc
Arvinas Inc
AstraZeneca Plc
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Bromodomain Pharmaceuticals Inc
C4 Therapeutics Inc
Checkpoint Therapeutics Inc
Constellation Pharmaceuticals Inc
CSPC Pharmaceutical Group Ltd
Epigene Therapeutics Inc
Kainos Medicine Inc
Ningbo Wenda Pharma
OHM Oncology
Oncopia Therapeutics LLC
Phio Pharmaceuticals Corp
Plexxikon Inc
Red Glead Discovery AB
Resverlogix Corp
SignalRx Pharmaceuticals Inc
Zenith Epigenetics Ltd